A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
NCT ID: NCT01688531
Last Updated: 2019-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
38 participants
INTERVENTIONAL
2012-08-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
NCT02073461
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
NCT01880320
Efficacy and Safety of CD5024 1% in Acne Vulgaris
NCT03034460
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671
Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel
NCT01885910
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CD0271 0.1%/CD1579 2.5% gel
Split-face design, one application a day for 6 months
CD0271 0.1%/CD1579 2.5% gel vehicle
one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
CD0271 0.1%/CD1579 2.5% gel vehicle
Split-face design, one application a day for 6 months
CD0271 0.1%/CD1579 2.5% gel
one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD0271 0.1%/CD1579 2.5% gel
one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
CD0271 0.1%/CD1579 2.5% gel vehicle
one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with active, moderate acne
Exclusion Criteria
* The subject has a severity of acne that is not amenable to treatment with CD0271-CD1579 (Screening)
18 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma Investigational site
Windsor, Ontario, Canada
Galderma Investigational site
Montreal, Quebec, Canada
Galderma Investigational site
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD.03.SPR.40183E
Identifier Type: -
Identifier Source: org_study_id
NCT01718665
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.